AI Article Synopsis
- Alzheimer's disease (AD) is linked to the buildup of beta amyloid (Abeta) in the brain, contributing to its debilitating effects.
- Targeting gamma-secretase, an enzyme that produces Abeta, could be a potential treatment strategy for AD.
- The text outlines a series of gamma-secretase inhibitors developed from a specific scaffold found through a ROCS search in a corporate database.
Article Abstract
Alzheimer's disease (AD) is a debilitating disease widely thought to be associated with the accumulation of beta amyloid (Abeta) in the brain. Inhibition of gamma-secretase, one of the enzymes responsible for Abeta production, may be a useful strategy for the treatment of AD. Described below is a series of gamma-secretase inhibitors designed from a scaffold identified by a ROCS [J. Comput. Chem.1996, 17, 1653] search of the corporate database.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2005.02.006 | DOI Listing |
Publication Analysis
Top Keywords
gamma-secretase inhibitors
8
molecular-modeling based
4
based design
4
design synthesis
4
synthesis activity
4
activity substituted
4
substituted piperidines
4
piperidines gamma-secretase
4
inhibitors alzheimer's
4
alzheimer's disease
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!